This is a working overview of obesity research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-22. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
== Equipment == The facility has a custom-made 3 mega-volt tandem accelerator mass spectrometer. It also has a 200 sample ion source, a high resolution, 120° injection magnet, a 90° high energy analysis magnet (mass-energy product 350 MeV-AMU), a 65°, 1.7 m radius electric analyzer and a 2 channel gas ionization detector. The spectrometer weighs around 44 tons and is around 25 metres long. The facility can be seen through a two-storey window in the lobby of the Advanced Research Complex. The spectrometer accelerates the isotopes to a very high speed with almost no contamination, thus allowing for the detection of trace isotopes at very low levels.
As an ontological principle (i.e., as a metaphysical concept about the nature of existence), it holds that all phenomena arise from other, pre-existing phenomena, and in turn current phenomena condition future phenomena. As such, everything in the world has been produced by causes. Traditionally, this is also closely connected to the Buddhist doctrine of rebirth, and how rebirth occurs without a fixed self or soul, but as a process conditioned by various phenomena and their relations. As an epistemological principle (i.e., as a theory about knowledge), it holds that there are no permanent and stable things, though there are classes of permanent phenomena viz. space (vacuum), cessations (including nirvana), and suchness (the absence of self, namely, anatta). Because everything is dependently originated, nothing is permanent (hence the Buddhist concept of impermanence, anicca) and nothing has any self-nature or essence (anatta). Consequently, all phenomena lack essence. In various traditions, this is closely associated with the doctrine of emptiness (śūnyatā). As a phenomenological or psychological principle, it refers to the workings of the mind and how suffering, craving, and self-view arise. This can refer to how different mental states condition each other over time, or to how different mental phenomena condition each other in a single moment.
Overall, there are various non-selective calcium channel blockers that help alleviate symptoms of hypertension, schizophrenia, cardiac arrhythmia, epilepsy, pain, asthma, bradycardia, angina pectoris and Alzheimer's disease. Although many of the therapeutic compounds' main target is not P-type channels, further research needs to determine if the clinical effects of these compounds are also influenced by the P-type channel blockage.
Santosh Lad Interview with Bangalore Mirror on Uttarakhand Relief Operations[link removed] Uttarakhand relief operations -Deccan Herald Uttarakhand Flood relief efforts. Santosh Lad visiting the epicenter to help and support. State Rushes Medical Aid to Uttarakhand Infrastructure Development Department of Karnataka Department of Information for Karnataka State Santosh Lad oath taking ceremony- NDTV List of M.L.A in Karnataka. Santosh S Lad member of Karnataka Legislative Assembly. 600 couples tie knot at mass marriage. Deccan Herald. Insurance cover for all in Kalghatagi constituency. Business Standard. Government is neglecting Kalghatgi, says Santosh Lad. The Hindu. Bollywood glitterati show up at Lad’s mass wedding. Bangalore Mirror.
We were of course glad to meet again and became close friends. On my side feelings developed gradually over the next two years. He seemed to have made his mind up much more quickly, however, and became even more keen when, in the autumn of 1910, rumours spread about that I had got engaged to a distant Spanish relative, Don Jaime, the Duke of Madrid. On hearing this, the Archduke came down post haste from his regiment at Brandýs and sought out his grandmother, Archduchess Maria Theresa, who was also my aunt and the natural confidante in such matters. He asked if the rumor was true and when told it was not, he replied, "Well, I had better hurry in any case or she will get engaged to someone else." Archduke Charles traveled to Villa Pianore and asked for Zita's hand and, on 13 June 1911, their engagement was announced at the Austrian court. Zita in later years recalled that after her engagement she had expressed to Charles her worries about the fate of the Austrian Empire and the challenges of the monarchy. Charles and Zita were married at the Schwarzau castle on 21 October 1911. Charles's great-uncle, the 81-year-old Emperor Franz Joseph I, attended the wedding. He was relieved to see an heir make a suitable marriage, and was in good spirits, even leading the toast at the wedding breakfast. Archduchess Zita soon conceived a son, and Otto was born on 20 November 1912. Seven more children followed in the next decade.
Sources: en.wikipedia.org
In June 1976, scientists from the Scripps Institution of Oceanography obtained the first evidence for submarine hydrothermal vents along the Galápagos Rift, a spur of the East Pacific Rise, on the Pleiades II expedition, using the Deep-Tow seafloor imaging system. In 1977, the first scientific papers on hydrothermal vents were published by scientists from the Scripps Institution of Oceanography; research scientist Peter Lonsdale published photographs taken from deep-towed cameras, and PhD student Kathleen Crane published maps and temperature anomaly data. Transponders were deployed at the site, which was nicknamed "Clam-bake", to enable an expedition to return the following year for direct observations with the DSV Alvin. Chemosynthetic ecosystems surrounding the Galápagos Rift submarine hydrothermal vents were first directly observed in 1977, when a group of marine geologists funded by the National Science Foundation returned to the Clambake sites. The principal investigator for the submersible study was Jack Corliss of Oregon State University. Corliss and Tjeerd van Andel from Stanford University observed and sampled the vents and their ecosystem on February 17, 1977, while diving in the DSV Alvin, a research submersible operated by the Woods Hole Oceanographic Institution (WHOI). Other scientists on the research cruise included Richard (Dick) Von Herzen and Robert Ballard of WHOI, Jack Dymond and Louis Gordon of Oregon State University, John Edmond and Tanya Atwater of the Massachusetts Institute of Technology, Dave Williams of the U.S.
== Applications == The Bergmann degradation is intended for and has been used as a method for peptide sequencing. It was also proposed for use in cleaving the 3,4-bond of the penicillin nucleus. The compound 2,2-dimethyl-6-phthalimido-3-penamyl isocyanate was arrived at through various means, including the Curtius rearrangement, and it was envisioned that it could undergo the Bergmann degradation to form the desired aldehyde as well as the urea by-product. Though the Bergmann degradation was indeed possible, it was discovered that simple dilute acid hydrolysis would suffice in forming the desired product.
The Umayyad Caliphate ruled al-Andalus as a province until its independence in 756 under the Emirate of Córdoba, which in 929 gave way to a caliphate that lasted until it fragmented into states known as taifas, collapsing in 1031, and most of what is now central and southern Portugal falling under the Taifa of Badajoz. The taifas were conquered by Muslim forces from North Africa, first completely by the Almoravids by 1115, who were in turn followed by the Almohads in the 1140s. Northern incursions also occurred during this period, with Viking raids recorded from 844 into the 11th century.
The cattle boats were examined, but the dates of the murders did not coincide with a single boat's movements, and the transfer of a crewman between boats was also ruled out. At the end of October, Robert Anderson asked police surgeon Thomas Bond to give his opinion on the extent of the murderer's surgical skill and knowledge. The opinion offered by Bond on the character of the "Whitechapel murderer" is the earliest surviving offender profile. Bond's assessment was based on his own examination of the most extensively mutilated victim and the post mortem notes from the four previous canonical murders. In his opinion the killer must have been a man of solitary habits, subject to "periodical attacks of homicidal and erotic mania", with the character of the mutilations possibly indicating "satyriasis". Bond also stated that "the homicidal impulse may have developed from a revengeful or brooding condition of the mind, or that religious mania may have been the original disease but I do not think either hypothesis is likely".
== Mechanism of action == Didanosine (ddI) is a nucleoside analogue of adenosine. It differs from other nucleoside analogues, because it does not have any of the regular bases, instead it has hypoxanthine attached to the sugar ring. Within the cell, ddI is phosphorylated to the active metabolite of dideoxyadenosine triphosphate, ddATP, by cellular enzymes. Like other anti-HIV nucleoside analogs, it acts as a chain terminator by incorporation and inhibits viral reverse transcriptase by competing with natural dATP.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.